Evidence map›Paper›PMID 33975958›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Genetically edited CD34

Maelig G Morvan, Fernando Teque, Lin Ye, Mary E Moreno, Jiaming Wang, Scott VandenBerg, Cheryl A Stoddart, Yuet Wai Kan, Jay A Levy

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Maelig G MorvanDepartment of Medicine, Division of Hematology and Oncology, University of California, San Francisco, CA 94143-1270.ORCID 0000-0001-5978-6894
Fernando TequeDepartment of Medicine, Division of Hematology and Oncology, University of California, San Francisco, CA 94143-1270.ORCID 0000-0001-5668-5270
Lin YeDepartment of Medicine, Institute of Human Genetics, University of California, San Francisco, CA 94143.ORCID 0000-0001-7351-8685
Mary E MorenoDepartment of Medicine, Division of Experimental Medicine, San Francisco General Hospital, University of California, San Francisco, CA 94110.ORCID 0000-0002-2398-5768
Jiaming WangDepartment of Medicine, Institute of Human Genetics, University of California, San Francisco, CA 94143.ORCID 0000-0002-5504-4276
Scott VandenBergHelen Diller Family Comprehensive Cancer Center, Biorepository and Tissue Biomarker Technology Core, University of California, San Francisco, CA 94143-0875.
Cheryl A StoddartDepartment of Medicine, Division of Experimental Medicine, San Francisco General Hospital, University of California, San Francisco, CA 94110.ORCID 0000-0002-7024-6044
Yuet Wai KanDepartment of Medicine, Institute of Human Genetics, University of California, San Francisco, CA 94143; yw.kan@ucsf.edu Jay.Levy@ucsf.edu.ORCID 0000-0003-0117-0100
Jay A LevyDepartment of Medicine, Division of Hematology and Oncology, University of California, San Francisco, CA 94143-1270; yw.kan@ucsf.edu Jay.Levy@ucsf.edu.ORCID 0000-0002-7584-3702
University of California, San Francisco · USSan Francisco General Hospital · US

Funding

Reprogramming iPS Cells with Exogenous and Endogenous Transcription Factor GenesP01DK088760 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRUENERT, DIETER C · 2011 to 2015
$6.5M
HIV Cure with CCr5 (-) Human IPS Hematopoietic Stem CellsR01AI102825 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEVY, JAY A · 2014 to 2016
$2.0M
HIV cure with CCR5 (-) human IPS hematopoietic stem cellsR56AI102825 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEVY, JAY A · 2012 to 2012
$518k
Heat shock protein 90 and HIV persistenceR21AI108398 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STODDART, CHERYL · 2013 to 2014
$518k
NIAID NIH HHS HHSN272201400002CNIAID NIH HHS R01 AI102825NIAID NIH HHS R21 AI108398NIAID NIH HHS R56 AI102825NIDDK NIH HHS P01 DK088760
6 · The paper itself

Abstract

Genetic editing of induced pluripotent stem (iPS) cells represents a promising avenue for an HIV cure. However, certain challenges remain before bringing this approach to the clinic. Among them, in vivo engraftment of cells genetically edited in vitro needs to be achieved. In this study, CD34

Indexed as

Genetic EngineeringHematopoietic Stem Cell TransplantationAnimalsCell DifferentiationCells, CulturedFemaleGene EditingHematopoietic Stem CellsHIV InfectionsHumansInduced Pluripotent Stem CellsMaleMiceCCR5genetic editingHIV resistanceiPS cellsteratoma

Identifiers

PMID33975958
PMCPMC8158014
OpenAlexW3160716283

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.